CTLA-4 in Regulatory T Cells for Cancer Immunotherapy.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have obtained durable responses in many cancers, making it possible to foresee their potential in improving the health of cancer patients. However, immunotherapies are currently limited to a minority of patients and there is a need to develop a better understanding of the basic molecular mechanisms and functions of pivotal immune regulatory molecules. Immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and regulatory T (T_reg) cells play pivotal roles in hindering the anticancer immunity. T_reg cells suppress antigen-presenting cells (APCs) by depleting immune stimulating cytokines, producing immunosuppressive cytokines and constitutively expressing CTLA-4. CTLA-4 molecules bind to CD80 and CD86 with a higher affini

SUBMITTER: Sobhani N 

PROVIDER: S-EPMC8005092 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature